Harrow Presents Positive Clinical Data for IHEEZO & BYOOVIZ

Harrow announced the presentation of three studies supporting IHEEZO and BYOOVIZ at the American Society of Retina Specialists (ASRS) 2026 Annual Meeting. Interim findings for IHEEZO showed encouraging trends toward less post-procedure pain and a better patient experience, with topline data from the larger QUELL study expected in Q4 2026. A real-world study for IHEEZO also found no increased endophthalmitis risk across nearly 20,000 injections, while Samsung Bioepis presented interim BYOOVIZ post-marketing surveillance data. These presentations expand the clinical and real-world evidence for Harrow's retina portfolio, reinforcing physician confidence and supporting product adoption.